[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626747":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":39,"locations":45,"responsibleParty":79,"collaborators":30,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":30,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":30,"enrollmentInfo":90,"targetDuration":30,"studyType":93,"phases":94,"briefSummary":97,"conditions":98,"keywords":30,"overallStatus":48,"whyStopped":30,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"TORL Biotherapeutics, LLC","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Monotherapy Dose Escalation","EXPERIMENTAL","TORL-5-700 Administered once every three weeks",[13],"Drug: TORL-5-700",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2: Monotherapy Expansion","TORL-5-700 at MTD\u002FRP2D Administered once every three weeks",[18],"Drug: TORL-5-700 at MTD\u002FRP2D",{"label":20,"type":10,"description":21,"interventionNames":22},"Part 3: Combination Evaluation","TORL-5-700 at MTD\u002FRP2D Administered once every three weeks in combination with another agent",[23],"Drug: TORL-5-700 at MTD\u002FRP2D in combination with another agent",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","TORL-5-700","Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"TORL-5-700 at MTD\u002FRP2D","Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)\u002FRecommended Phase 2 Dose (RP2D) Administered once every three weeks",[15],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"TORL-5-700 at MTD\u002FRP2D in combination with another agent","Part 3: Combination Evaluation - TORL-5-700 at MTD\u002FRP2D administered every three weeks in combination with another agent",[20],[40],{"name":41,"role":42,"phone":43,"phoneExt":30,"email":44},"Timothy Welliver, M.D.","CONTACT","(310) 598-5969","timothy.welliver@torlbio.com",[46,60,69],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":30},"UCLA","RECRUITING","Santa Monica","California","90404","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-118.49138,34.01949,{"lat":58,"lon":57},{"facility":61,"status":48,"city":62,"state":50,"zip":63,"country":52,"countryCode":53,"cosmosGeoPoint":64,"geoPoint":68,"contacts":30},"Stanford University","Stanford","94305",{"type":55,"coordinates":65},[66,67],-122.16608,37.42411,{"lat":67,"lon":66},{"facility":70,"status":48,"city":71,"state":72,"zip":73,"country":52,"countryCode":53,"cosmosGeoPoint":74,"geoPoint":78,"contacts":30},"Sarah Cannon Research Institute","Nashville","Tennessee","37203",{"type":55,"coordinates":75},[76,77],-86.78444,36.16589,{"lat":77,"lon":76},{"type":80,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100626747","phase-1-a-study-of-torl-5-700-in-relapsedrefractory-non-hodgkins-lymphoma-100626747",false,"NCT07439653","A Study of TORL-5-700 in Relapsed\u002FRefractory Non Hodgkin's Lymphoma","A Phase 1\u002F2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.\n* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.\n* At least 1 measurable lesion per Lugano criteria.\n* Tumor tissue is available.\n* Adequate organ function\n\nExclusion Criteria:\n\n* T-cell lymphoma\n* CLL or SL\n* Burkitt lymphoma and high-grade B-cell lymphoma\n* CNS involvement\n* Peripheral neuropathy \\> Grade 2\n* Uncontrolled medical conditions\n* Viral infections","ALL","18 Years",{"count":91,"type":92},155,"ESTIMATED","INTERVENTIONAL",[95,96],"PHASE1","PHASE2","A Phase 1\u002F2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R\u002FR NHL",[99],"Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","2026-06-09",{"date":102,"type":103},"2026-06-11","ACTUAL",{"date":105,"type":103},"2026-03-31",{"date":107,"type":92},"2029-09-30",{"name":5,"class":6},3]